Make confident go/no-go decisions earlier
Grounded in evidence you can defend.
Unify biology, chemistry, pharmacology, and competitive intelligence in a single platform. Cortellis Drug Discovery Intelligence assesses the likelihood of drug success early by transforming fragmented data into actionable insights.
of Phase II/III trials fail due to efficacy/safety. Assess rationale early.
of failures stem from weak target-disease links. Validate mechanisms.
years of expert curated data backing every insight.
Apply agentic AI to synthesize evidence and surface what matters.
Designed for biologists, medicinal chemists, and pharmacologists to find actionable insight.
Drill down to answers with granular indexing for early discovery.
Prioritize targets using dynamic visualizations of disease mechanisms.
Deep coverage spanning 27+ therapy areas and global sources.
Identify similar compounds and refine ADME and PK profiles.
The Cortellis Drug Discovery Assistant provides AI-guided insights that go beyond simple search. Surface, connect, and summarize relevant evidence faster—anchored entirely in expertly curated content you already trust.
See how the AI Assistant quickly identifies discontinued GLP-1 programs, examines their development stages, and explores clustering around specific mechanisms or combination strategies.
Discover how to identify active PROTAC therapies, uncover leading companies and programs, explore frequently targeted E3 ligases, and analyze program counts for given targets like BTK.
Learn to identify organizations developing preclinical ADCs, instantly build tables summarizing linker and payload combinations, and interact in multiple languages to evaluate competitive activity.
Biology, chemistry, and pharmacology integrated. Content is extracted, summarized, and indexed by scientific experts.